This Thursday, the prestigious British Museum in London will play host to Europe’s leading psychedelic medicine conference – the PSYCH Symposium.
This thought-leadership event brings together the industry’s most influential figures, fostering a vibrant atmosphere of connection and collaboration.
Designed to cut through the noise and identify real opportunities, the PSYCH Symposium shines a spotlight on key players, innovations, and milestones in psychedelic medicine.
It provides investors with invaluable insights, as well as a platform to understand the emerging landscape of this rapidly advancing field.
Among the key areas of focus will be the socioeconomic cost-benefits of modernising regulations and improving access to psychedelic medicine.
These discussions will illuminate the broad impact of such policy changes, giving stakeholders a holistic understanding of the landscape.
The PSYCH Symposium has a lofty aim: to expedite the adoption of psychedelic healthcare.
In a rapidly evolving medical landscape, psychedelic treatments are gaining recognition for their potential in addressing mental health conditions like depression, anxiety, and PTSD.
The symposium will explore these breakthroughs, providing a robust forum for sharing research findings and clinical experiences.
As Europe’s foremost psychedelic medicine conference, the PSYCH Symposium is a pivotal gathering for anyone invested in the future of mental health treatments.
From researchers, clinicians, and policymakers to investors and biotech companies, the event offers attendees the unique opportunity to participate in shaping this burgeoning field.
Those scheduled to speak include Charlotte Nichols MP, a campaigner for the rescheduling of psilocybin who recently led a debate regarding this matter in the House of Commons.
Nichols will be joined by Dr. Chris Timmerman whose recent work on neuroimaging of DMT has been widely shared. Professor Robin Carhart-Harris, who led the first research into psilocybin for forty years, is also due to speak.
London’s PSYCH Symposium 2023 is set to be a landmark event in psychedelic healthcare.